A Co-Founder of Athos Therapeutics, Dr. Michael E. Jung, Wins the National Academy of Sciences Award for Chemistry in Service to Society
30 April 2025, 11:30 am ET LOS ANGELES, April 30, 2025 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, is honored to announce that Dr. Michael E. Jung, a co-founder of Athos, was awarded the National Academy of Sciences Award for […]
CIOs look beyond ‘Big 3’ cloud providers for AI innovation
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activities No serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos’ Proprietary […]
AI-based Small Molecule Therapeutics Pioneer Athos Therapeutics Selects Vultr for Secure AI Training in the Cloud
Athos accelerates the development of precision therapeutics for patients with immune-mediated diseases and cancer by scaling its autonomous AI analytical platform WEST PALM BEACH, Fla.–(BUSINESS WIRE)–Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and […]
Athos Therapeutics Announces the Autonomization of their Artificial Intelligence and Machine Learning Platforms
The Athos Computational Platforms are now Disease Agnostic with an AI/ML framework powered by Autonomous Transcriptomics and Proteomics able to Integrate and Learn from Diverse Multi-Omic Data Domains LOS ANGELES, March 5, 2024 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of Artificial Intelligence (AI) and Machine Learning (ML)-based precision […]
Laurence Stein, Former Partner and Managing Director of Goldman Sachs, Appointed to the Board of Directors of Athos Therapeutics
LOS ANGELES, February 13, 2024 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that Laurence Stein, has been named to the Company’s Board of Directors and will serve as Head of its Business Strategy […]
All Three Athos Co-Founders Named to Stanford’s List of the World’s Top 2% of Scientists
LOS ANGELES, CA / ACCESSWIRE / October 12, 2023 / Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that each one of the three co-founders of Athos has been named to Stanford University’s prestigious “Top 2%” […]
Athos Student Internship Program
The internship program was designed to expose students to Athos’s unique, innovative, and diverse interdisciplinary approach to science and drug development, and to create a bridge for students between academia and the professional world. We provide invaluable and practical experiences such as how to pipette and use scientific equipment, how to create different concentrations of […]
Tony Zingale, Noted Chief Executive Officer and Entrepreneur, Appointed as an Observer to the Board of Directors of Athos Therapeutics
LOS ANGELES, May 17, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that Tony Zingale, a veteran software executive, was appointed as an observer to the Board of Directors of Athos Therapeutics. “Athos […]
Athos Therapeutics Announces Dosing of the First Patient in the First-In-Human Phase 1 Clinical Trial of ATH-063
ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease – 27 April 2023, 11:30 am ET LOS ANGELES, April 27, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics […]